| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
BIIB091 possesses an IC50 of 6.9 nM, which allows it to inhibit PLCγ2 phosphorylation in the Ramos human B cell line [1]. For PBMC, BIIB091 has an IC50 of 6.9 nM, blocking anti-IgM-stimulated CD69 activation [1]. For pure primary neutrophils, BIIB091 has an IC50 of 4.5 nM, which reduces FcγR-induced ROS generation [1]. When human monocytes are modeled with FcγR agonists, such as coated human IgG (all FcηR, IC50=5.6 nM), anti-CD16 (FcγRIII, IC50=8.0 nM), anti-CD64 (FcγRI, IC50=3.1 nM), and cross-linked anti-CD16 (FcγRIII, IC50=1.3 nM), BIIB091 suppresses FcγRI- and FcγRIII-mediated TNFα secretion [1]. According to blood tests, BIIB091 reduces BTK phosphorylation (IC50=24 nM) and prevents basophil activation induced by FcεR and BCR-mediated B cells. It also inhibits CD69 and CD63 expression (IC50=71 nM and IC50=82 nM, respectively)).
|
|---|---|
| ln Vivo |
BIIB091 (0.03-30 mg/kg; administered orally twice daily for 10 days) lowers anti-NP IgM antibody titers in TI (88%, 77%, 59%, 59%, 44%, 34%, and 22% ) -2 immunological model[1]. Pharmacokinetics (h) of BIIB091 in species IV (1 mg/kg) PO (5 mg/kg) AUCinf (h·ng/mL) CL ( mL/min/kg) CL %QH Vdss (L/kg) Tmax (h) Cmax (ng/mL) AUCinf (h·ng/mL) %F Rat 2.1 748 10 22 0.4 0.9 693 1522 42 Cynomolgus monkey 1.1 943 18 44 0.7 0.33 1104 1446 31 Dog 6.0 1675 12 33 1.7 1.6 1440 6075 89
|
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice immunized with thymus-independent type 2 (TI-2) antigen NP-Ficoll [1]
Doses: 0.03 , 0.1, 0.3, 1, 10, 30 mg/kg CMC/Tween suspension formulation Dosing: Orally twice (two times) daily for 10 days Experimental Results: A significant decrease in anti-NP IgM antibody titers was observed (88%, 77% , 59%, 59%, 44%, 34%, and 22%). |
| References |
| Molecular Formula |
C28H34N10O2
|
|---|---|
| Molecular Weight |
542.64
|
| Exact Mass |
542.286
|
| CAS # |
2247614-80-6
|
| PubChem CID |
135355941
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
40
|
| Complexity |
869
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1(C(C)(C)C)C=C(C(N[C@H]2C3=CC=C(C4C=CN=C(NC5=CN(C)N=C5)N=4)C=C3CN(C3COC3)CC2)=O)N=N1
|
| InChi Key |
JSAQBOQCZJHWMA-XMMPIXPASA-N
|
| InChi Code |
InChI=1S/C28H34N10O2/c1-28(2,3)38-15-25(34-35-38)26(39)32-24-8-10-37(21-16-40-17-21)13-19-11-18(5-6-22(19)24)23-7-9-29-27(33-23)31-20-12-30-36(4)14-20/h5-7,9,11-12,14-15,21,24H,8,10,13,16-17H2,1-4H3,(H,32,39)(H,29,31,33)/t24-/m1/s1
|
| Chemical Name |
1-tert-butyl-N-[(5R)-8-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-2-(oxetan-3-yl)-1,3,4,5-tetrahydro-2-benzazepin-5-yl]triazole-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~230.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8428 mL | 9.2142 mL | 18.4284 mL | |
| 5 mM | 0.3686 mL | 1.8428 mL | 3.6857 mL | |
| 10 mM | 0.1843 mL | 0.9214 mL | 1.8428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
